US2019038813A1PendingUtilityA1

Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin

67
Assignee: ND PARTNERS LLCPriority: Nov 2, 2004Filed: Mar 5, 2018Published: Feb 7, 2019
Est. expiryNov 2, 2024(expired)· nominal 20-yr term from priority
Inventors:Frank R. Prosl
A61P 7/02A61P 31/04A61P 31/00A61K 31/727A61L 29/16A01N 43/88A61K 31/185A61K 31/18A61L 2300/406A61L 29/00A61L 2300/204A01N 25/02A61L 29/043A61K 2300/00
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to inhibiting or preventing infection and protecting against patency complications after a blood catheter has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising: (A) at least one taurinamide derivative, (B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof; and (C) heparin at a low concentration.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A locking solution composition for treating and preventing infection and flow reduction in blood catheters comprising a solution of:
 a. at least one taurinamide derivative;   b. a biologically acceptable acid and a biologically acceptable salt of said acid in a combination that brings the pH of the combination into a range that enhances antimicrobial activity of the taurinamide derivative; and   c. low concentration heparin, wherein the heparin concentration is sufficient to prevent reactions of the taurinamide derivative with stagnant blood but low enough that expulsion and/or spillage of the solution into a patient's bloodstream carries a low risk of patient hemorrhage.   
     
     
         2 . The composition of  claim 1  wherein the biologically acceptable acid is chosen from the group citric acid and lactic acid and the biologically acceptable salt is chosen from the group citrate and lactate. 
     
     
         3 . The composition of  claim 1  wherein the taurinamide derivative is taurolidine, the biologically acceptable acid is citric acid, the biologically acceptable salt is citrate, and the pH range is 5.2 to 6.5. 
     
     
         4 . The composition of  claim 3  wherein low concentration heparin is in the range of 50 to 2500 units per ml. 
     
     
         5 . The composition of  claim 4  wherein low concentration heparin is in the range of 50 to 1750 units per ml. 
     
     
         6 . The composition of  claim 4  wherein low concentration heparin is in the range of 50 to 500 units per ml. 
     
     
         7 . The composition of  claim 4  wherein the low concentration heparin is in the range 50 to 150 units per ml. 
     
     
         8 . A method of enhancing the antimicrobial activity and resistance to flow reduction produced by a catheter locking solution comprising taurolidine in combination with citrate and citric acid by maintaining the pH in the range of 5.2 to 6.5 and of protecting a catheter against taurolidine reaction with blood therein by adding low concentration heparin. 
     
     
         9 . The method of  claim 8  wherein low concentration heparin is in the range of 50 to 2500 units per ml. 
     
     
         10 . The method of  claim 8  in which the low concentration heparin is in the range of 50 units

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.